Foghorn Therapeutics

Foghorn Therapeutics financials

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Stock Price

$4.7

2023-03-24

Market Capitalization

$198.1 M

2023-03-24

Revenue

$1.3 M

FY, 2021

CreditSafe score

Score changed on Mar 28, 2023

Premium Content

USD	FY, 2018	FY, 2019	FY, 2020	FY, 2021
Revenue			430.0K	1.3M
General and administrative expense	4.8M	6.7M	11.2M	21.7M
Operating expense total	26.0M	51.1M	69.0M
EBIT	(26.0M)	(51.1M)	(68.5M)	(100.7M)
EBIT margin, %			-15937.4%
Interest expense	371.0K	540.0K
Net Income	(26.3M)	(51.1M)	(68.8M)	(101.3M)
EPS	(8.9)	(12.2)

Company name	Date	Deal size
Lorem	Dec 23, 2021	$40.0M
Ipsum	Jan 18, 2022	$30.0M
Lorem Ipsum	Feb 18, 2022	$25.0M
Dolor	Oct 21, 2021	$60.0M
Premium Content View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more